Cargando…

Structural Basis of Activin Receptor-Like Kinase 2 (R206H) Inhibition by Bis-heteroaryl Pyrazole-Based Inhibitors for the Treatment of Fibrodysplasia Ossificans Progressiva Identified by the Integration of Ligand-Based and Structure-Based Drug Design Approaches

[Image: see text] Fibrodysplasia ossificans progressiva (FOP) is a rare but severe genetic disorder in which acute inflammation elicits progressive heterotopic ossification in the muscles, tendons, and ligaments. Classic FOP is caused by the R206H mutation in ALK2/ACVR1. While several activin recept...

Descripción completa

Detalles Bibliográficos
Autores principales: Sato, Tomohiro, Sekimata, Katsuhiko, Sakai, Naoki, Watanabe, Hisami, Mishima-Tsumagari, Chiemi, Taguri, Tomonori, Matsumoto, Takehisa, Fujii, Yoshifumi, Handa, Noriko, Tanaka, Akiko, Shirouzu, Mikako, Yokoyama, Shigeyuki, Hashizume, Yoshinobu, Miyazono, Kohei, Koyama, Hiroo, Honma, Teruki
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Chemical Society 2020
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7254505/
https://www.ncbi.nlm.nih.gov/pubmed/32478230
http://dx.doi.org/10.1021/acsomega.9b04245
_version_ 1783539552943603712
author Sato, Tomohiro
Sekimata, Katsuhiko
Sakai, Naoki
Watanabe, Hisami
Mishima-Tsumagari, Chiemi
Taguri, Tomonori
Matsumoto, Takehisa
Fujii, Yoshifumi
Handa, Noriko
Tanaka, Akiko
Shirouzu, Mikako
Yokoyama, Shigeyuki
Hashizume, Yoshinobu
Miyazono, Kohei
Koyama, Hiroo
Honma, Teruki
author_facet Sato, Tomohiro
Sekimata, Katsuhiko
Sakai, Naoki
Watanabe, Hisami
Mishima-Tsumagari, Chiemi
Taguri, Tomonori
Matsumoto, Takehisa
Fujii, Yoshifumi
Handa, Noriko
Tanaka, Akiko
Shirouzu, Mikako
Yokoyama, Shigeyuki
Hashizume, Yoshinobu
Miyazono, Kohei
Koyama, Hiroo
Honma, Teruki
author_sort Sato, Tomohiro
collection PubMed
description [Image: see text] Fibrodysplasia ossificans progressiva (FOP) is a rare but severe genetic disorder in which acute inflammation elicits progressive heterotopic ossification in the muscles, tendons, and ligaments. Classic FOP is caused by the R206H mutation in ALK2/ACVR1. While several activin receptor-like kinase 2 (ALK2) inhibitors were found to be efficacious in animal models of FOP, most of the ALK2 (R206H) inhibitors lacked sufficient oral bioavailability for efficacy. Previously, the synthesis of a series of novel bis-heteroaryl pyrazole-based ALK2 (R206H) inhibitors that achieved both substantial potency and an improved ADMET profile was reported. In the present study, the detailed procedure of the in silico approach employed to identify the initial bis-heteroaryl pyrazole-based ALK2 (R206H) inhibitor RK-59638 and the analysis of the ALK2 (R206H) RK-59638 complex structure to guide the synthetic optimization of the chemical series, obtaining RK-71807 showing improved potency and metabolic stability, were described. According to the initial in silico screening, the screening efficiencies and chemical diversity of the hit compounds of both ligand-based and structure-based methods were evaluated. Then, X-ray structures of ALK2 (R206H) and the inhibitors were analyzed to assess the structure–activity relationships of the synthesized compounds. The 3D-RISM analysis indicated the existence of the additional hydrogen bond via water molecules restricting the attachment point in the pyrazole scaffold. The quantum mechanics calculation of the newly determined ALK2 (R206H) RK-71807 complex structure using a fragment molecular orbital method and pair interaction energy decomposition analysis was employed to evaluate the interaction energies between the inhibitor and each of the amino acid residues and decompose them to electrostatic, exchange-repulsion, and charge transfer energies. The pattern of decomposed interaction energies was then compared to that formed by RK-59638 and LDN-193189 to investigate the structural basis of ALK2 (R206H) inhibition.
format Online
Article
Text
id pubmed-7254505
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher American Chemical Society
record_format MEDLINE/PubMed
spelling pubmed-72545052020-05-29 Structural Basis of Activin Receptor-Like Kinase 2 (R206H) Inhibition by Bis-heteroaryl Pyrazole-Based Inhibitors for the Treatment of Fibrodysplasia Ossificans Progressiva Identified by the Integration of Ligand-Based and Structure-Based Drug Design Approaches Sato, Tomohiro Sekimata, Katsuhiko Sakai, Naoki Watanabe, Hisami Mishima-Tsumagari, Chiemi Taguri, Tomonori Matsumoto, Takehisa Fujii, Yoshifumi Handa, Noriko Tanaka, Akiko Shirouzu, Mikako Yokoyama, Shigeyuki Hashizume, Yoshinobu Miyazono, Kohei Koyama, Hiroo Honma, Teruki ACS Omega [Image: see text] Fibrodysplasia ossificans progressiva (FOP) is a rare but severe genetic disorder in which acute inflammation elicits progressive heterotopic ossification in the muscles, tendons, and ligaments. Classic FOP is caused by the R206H mutation in ALK2/ACVR1. While several activin receptor-like kinase 2 (ALK2) inhibitors were found to be efficacious in animal models of FOP, most of the ALK2 (R206H) inhibitors lacked sufficient oral bioavailability for efficacy. Previously, the synthesis of a series of novel bis-heteroaryl pyrazole-based ALK2 (R206H) inhibitors that achieved both substantial potency and an improved ADMET profile was reported. In the present study, the detailed procedure of the in silico approach employed to identify the initial bis-heteroaryl pyrazole-based ALK2 (R206H) inhibitor RK-59638 and the analysis of the ALK2 (R206H) RK-59638 complex structure to guide the synthetic optimization of the chemical series, obtaining RK-71807 showing improved potency and metabolic stability, were described. According to the initial in silico screening, the screening efficiencies and chemical diversity of the hit compounds of both ligand-based and structure-based methods were evaluated. Then, X-ray structures of ALK2 (R206H) and the inhibitors were analyzed to assess the structure–activity relationships of the synthesized compounds. The 3D-RISM analysis indicated the existence of the additional hydrogen bond via water molecules restricting the attachment point in the pyrazole scaffold. The quantum mechanics calculation of the newly determined ALK2 (R206H) RK-71807 complex structure using a fragment molecular orbital method and pair interaction energy decomposition analysis was employed to evaluate the interaction energies between the inhibitor and each of the amino acid residues and decompose them to electrostatic, exchange-repulsion, and charge transfer energies. The pattern of decomposed interaction energies was then compared to that formed by RK-59638 and LDN-193189 to investigate the structural basis of ALK2 (R206H) inhibition. American Chemical Society 2020-05-12 /pmc/articles/PMC7254505/ /pubmed/32478230 http://dx.doi.org/10.1021/acsomega.9b04245 Text en Copyright © 2020 American Chemical Society This is an open access article published under an ACS AuthorChoice License (http://pubs.acs.org/page/policy/authorchoice_termsofuse.html) , which permits copying and redistribution of the article or any adaptations for non-commercial purposes.
spellingShingle Sato, Tomohiro
Sekimata, Katsuhiko
Sakai, Naoki
Watanabe, Hisami
Mishima-Tsumagari, Chiemi
Taguri, Tomonori
Matsumoto, Takehisa
Fujii, Yoshifumi
Handa, Noriko
Tanaka, Akiko
Shirouzu, Mikako
Yokoyama, Shigeyuki
Hashizume, Yoshinobu
Miyazono, Kohei
Koyama, Hiroo
Honma, Teruki
Structural Basis of Activin Receptor-Like Kinase 2 (R206H) Inhibition by Bis-heteroaryl Pyrazole-Based Inhibitors for the Treatment of Fibrodysplasia Ossificans Progressiva Identified by the Integration of Ligand-Based and Structure-Based Drug Design Approaches
title Structural Basis of Activin Receptor-Like Kinase 2 (R206H) Inhibition by Bis-heteroaryl Pyrazole-Based Inhibitors for the Treatment of Fibrodysplasia Ossificans Progressiva Identified by the Integration of Ligand-Based and Structure-Based Drug Design Approaches
title_full Structural Basis of Activin Receptor-Like Kinase 2 (R206H) Inhibition by Bis-heteroaryl Pyrazole-Based Inhibitors for the Treatment of Fibrodysplasia Ossificans Progressiva Identified by the Integration of Ligand-Based and Structure-Based Drug Design Approaches
title_fullStr Structural Basis of Activin Receptor-Like Kinase 2 (R206H) Inhibition by Bis-heteroaryl Pyrazole-Based Inhibitors for the Treatment of Fibrodysplasia Ossificans Progressiva Identified by the Integration of Ligand-Based and Structure-Based Drug Design Approaches
title_full_unstemmed Structural Basis of Activin Receptor-Like Kinase 2 (R206H) Inhibition by Bis-heteroaryl Pyrazole-Based Inhibitors for the Treatment of Fibrodysplasia Ossificans Progressiva Identified by the Integration of Ligand-Based and Structure-Based Drug Design Approaches
title_short Structural Basis of Activin Receptor-Like Kinase 2 (R206H) Inhibition by Bis-heteroaryl Pyrazole-Based Inhibitors for the Treatment of Fibrodysplasia Ossificans Progressiva Identified by the Integration of Ligand-Based and Structure-Based Drug Design Approaches
title_sort structural basis of activin receptor-like kinase 2 (r206h) inhibition by bis-heteroaryl pyrazole-based inhibitors for the treatment of fibrodysplasia ossificans progressiva identified by the integration of ligand-based and structure-based drug design approaches
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7254505/
https://www.ncbi.nlm.nih.gov/pubmed/32478230
http://dx.doi.org/10.1021/acsomega.9b04245
work_keys_str_mv AT satotomohiro structuralbasisofactivinreceptorlikekinase2r206hinhibitionbybisheteroarylpyrazolebasedinhibitorsforthetreatmentoffibrodysplasiaossificansprogressivaidentifiedbytheintegrationofligandbasedandstructurebaseddrugdesignapproaches
AT sekimatakatsuhiko structuralbasisofactivinreceptorlikekinase2r206hinhibitionbybisheteroarylpyrazolebasedinhibitorsforthetreatmentoffibrodysplasiaossificansprogressivaidentifiedbytheintegrationofligandbasedandstructurebaseddrugdesignapproaches
AT sakainaoki structuralbasisofactivinreceptorlikekinase2r206hinhibitionbybisheteroarylpyrazolebasedinhibitorsforthetreatmentoffibrodysplasiaossificansprogressivaidentifiedbytheintegrationofligandbasedandstructurebaseddrugdesignapproaches
AT watanabehisami structuralbasisofactivinreceptorlikekinase2r206hinhibitionbybisheteroarylpyrazolebasedinhibitorsforthetreatmentoffibrodysplasiaossificansprogressivaidentifiedbytheintegrationofligandbasedandstructurebaseddrugdesignapproaches
AT mishimatsumagarichiemi structuralbasisofactivinreceptorlikekinase2r206hinhibitionbybisheteroarylpyrazolebasedinhibitorsforthetreatmentoffibrodysplasiaossificansprogressivaidentifiedbytheintegrationofligandbasedandstructurebaseddrugdesignapproaches
AT taguritomonori structuralbasisofactivinreceptorlikekinase2r206hinhibitionbybisheteroarylpyrazolebasedinhibitorsforthetreatmentoffibrodysplasiaossificansprogressivaidentifiedbytheintegrationofligandbasedandstructurebaseddrugdesignapproaches
AT matsumototakehisa structuralbasisofactivinreceptorlikekinase2r206hinhibitionbybisheteroarylpyrazolebasedinhibitorsforthetreatmentoffibrodysplasiaossificansprogressivaidentifiedbytheintegrationofligandbasedandstructurebaseddrugdesignapproaches
AT fujiiyoshifumi structuralbasisofactivinreceptorlikekinase2r206hinhibitionbybisheteroarylpyrazolebasedinhibitorsforthetreatmentoffibrodysplasiaossificansprogressivaidentifiedbytheintegrationofligandbasedandstructurebaseddrugdesignapproaches
AT handanoriko structuralbasisofactivinreceptorlikekinase2r206hinhibitionbybisheteroarylpyrazolebasedinhibitorsforthetreatmentoffibrodysplasiaossificansprogressivaidentifiedbytheintegrationofligandbasedandstructurebaseddrugdesignapproaches
AT tanakaakiko structuralbasisofactivinreceptorlikekinase2r206hinhibitionbybisheteroarylpyrazolebasedinhibitorsforthetreatmentoffibrodysplasiaossificansprogressivaidentifiedbytheintegrationofligandbasedandstructurebaseddrugdesignapproaches
AT shirouzumikako structuralbasisofactivinreceptorlikekinase2r206hinhibitionbybisheteroarylpyrazolebasedinhibitorsforthetreatmentoffibrodysplasiaossificansprogressivaidentifiedbytheintegrationofligandbasedandstructurebaseddrugdesignapproaches
AT yokoyamashigeyuki structuralbasisofactivinreceptorlikekinase2r206hinhibitionbybisheteroarylpyrazolebasedinhibitorsforthetreatmentoffibrodysplasiaossificansprogressivaidentifiedbytheintegrationofligandbasedandstructurebaseddrugdesignapproaches
AT hashizumeyoshinobu structuralbasisofactivinreceptorlikekinase2r206hinhibitionbybisheteroarylpyrazolebasedinhibitorsforthetreatmentoffibrodysplasiaossificansprogressivaidentifiedbytheintegrationofligandbasedandstructurebaseddrugdesignapproaches
AT miyazonokohei structuralbasisofactivinreceptorlikekinase2r206hinhibitionbybisheteroarylpyrazolebasedinhibitorsforthetreatmentoffibrodysplasiaossificansprogressivaidentifiedbytheintegrationofligandbasedandstructurebaseddrugdesignapproaches
AT koyamahiroo structuralbasisofactivinreceptorlikekinase2r206hinhibitionbybisheteroarylpyrazolebasedinhibitorsforthetreatmentoffibrodysplasiaossificansprogressivaidentifiedbytheintegrationofligandbasedandstructurebaseddrugdesignapproaches
AT honmateruki structuralbasisofactivinreceptorlikekinase2r206hinhibitionbybisheteroarylpyrazolebasedinhibitorsforthetreatmentoffibrodysplasiaossificansprogressivaidentifiedbytheintegrationofligandbasedandstructurebaseddrugdesignapproaches